CROMA at ESCRS

Article

During this year?s ESCRS in Vienna CROMA will highlight its history of 35 years as a key player in ophthalmology.

During this year´s ESCRS in Vienna CROMA will highlight its history of 35 years as a key player in ophthalmology. Having started from a small pharmacy, the family-owned company reached the level of big international competitors, constantly developing innovative and unique products for markets all over the world.

Currently, CROMA is performing clinical studies, involving a new product, based on the so-called Thiomers, a unique technology combining macromolecules such as hyaluronic acid to a human amino acid (cysteine) for different ophthalmic applications. First results will be presented during the CROMA satellite symposium.

In the field of intraocular lenses, CROMA is launching two new models in 2011. The new hydrophobic blue-light filtering IOL “EYE-Cee One” has been successfully introduced in May. First clinical experiences will be shared during the ESCRS lunch symposium. CROMA will further make use of the ESCRS in Vienna to internationally launch its new multifocal IOL.

CROMA satellite symposium:

“Amazing Advances in Ocular Excellence”
Sunday, 18th September, 2011
1:00 pm – 2:00 pm
Room Stolz 1

CROMA - Bausch and Lomb joint satellite symposium:

“Bromfenac, a new potent Tool in Inflammation Control post cararact surgery”
Sunday, 18th September, 2011
1:00 pm – 2:00 pm
Room Strauss 3

Click here to register online.

Click here to email CROMA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.